Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle”In the company’s words, NCT04207983 on ClinicalTrials.gov
- Tested for
- Non-infectious Uveitis
- Main trialPhase 2
- “The objective of the study is to evaluate the efficacy and safety of two different treatment regimens of EYS606.”In the company’s words, NCT04207983 on ClinicalTrials.gov
Other drugs for Non-infectious Uveitis
- ApremilastAmgen · Phase 3
- BaricitinibEli Lilly · Phase 3
- Brepocitinib QDPriovant Therapeutics, Inc. · Phase 3
- Hemay005Ganzhou Hemay Pharmaceutical Co., Ltd · Phase 3
- FXS5626Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Phase 2
- GenakumabChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 5 Oct 2021 | A 48 Week Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic Non-infectious Uveitis (CNIU) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026